- Conditions
- Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
- Interventions
- Thor laser atherectomy
- Device
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 29
- States / cities
- St. Helena, California • Aurora, Colorado • Bradenton, Florida + 24 more
Clinical trials in Philadelphia, Pennsylvania
This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Philadelphia
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Parkinson's Disease
- Interventions
- Prasinezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
- Conditions
- Clostridoides Difficile Associated Disease
- Interventions
- C.difficile vaccine, Saline Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 32,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 142
- States / cities
- Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
- Conditions
- Remote vs. In-Person, Remote Visits, In-person Visits
- Interventions
- Combination Nicotine Replacement Therapy (patch and lozenge)
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Philadelphia, Pennsylvania
- Conditions
- Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Ann Arbor, Michigan + 5 more
- Conditions
- Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- AP01
- Combination Product
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
- Interventions
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 20
- States / cities
- Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Alcohol Use Disorder, Alcohol Withdrawal, Ketosis
- Interventions
- ketone supplement "D-beta-hydroxybutryric acid and R-1,3 butanediol" 12g of ketones,, magnetic resonance imaging session, Placebo beverage
- Dietary Supplement · Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Participants, Atopic Dermatitis
- Interventions
- PF-07832837, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Anaheim, California • San Diego, California • Miami, Florida + 2 more
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Mizagliflozin 5 mg, Mizagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Vogenx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Chula Vista, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- Focal Epilepsy
- Interventions
- XEN1101
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more